L-thyroxine(T4)
From DrugPedia: A Wikipedia for Drug discovery
Line 1: | Line 1: | ||
- | Pubchem(5819) | + | '''Pubchem'''(5819) |
+ | |||
The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. | The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. | ||
Line 21: | Line 22: | ||
|} | |} | ||
- | KEGG Pathway(C01829) | + | '''KEGG Pathway'''(C01829) |
- | Tyrosine metabolism | + | *Tyrosine metabolism |
- | Neuroactive ligand-receptor interaction | + | *Neuroactive ligand-receptor interaction |
- | Autoimmune thyroid disease | + | *Autoimmune thyroid disease |
- | Comment Thyroid hormone | + | |
- | synthesized on thyroglobulin | + | '''Comment''' Thyroid hormone synthesized on thyroglobulin |
{| border="1;width:100%; height:200px;style=text-align:center" | {| border="1;width:100%; height:200px;style=text-align:center" | ||
Line 38: | Line 39: | ||
|1ICT | |1ICT | ||
|Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 | |Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 | ||
- | |||
|- | |- | ||
|19209 | |19209 | ||
|1IE4 | |1IE4 | ||
|Wojtczak ACrystal structure of rat transthyretin at 2.5 A resolution: first report on a unique tetrameric structureActa Biochim. Pol. v44, p.505-517 | |Wojtczak ACrystal structure of rat transthyretin at 2.5 A resolution: first report on a unique tetrameric structureActa Biochim. Pol. v44, p.505-517 | ||
- | |||
|- | |- | ||
|22897 | |22897 | ||
|1HK1 | |1HK1 | ||
- | | | + | |Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
|- | |- | ||
|22898 | |22898 | ||
|1HK2 | |1HK2 | ||
- | | | + | |Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
|- | |- | ||
|22893 | |22893 | ||
|1HK3 | |1HK3 | ||
- | | | + | |Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
|- | |- | ||
|22900 | |22900 | ||
|1HK4 | |1HK4 | ||
- | | | + | |Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
|- | |- | ||
|22901 | |22901 | ||
|1HK5 | |1HK5 | ||
|Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 | |Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 | ||
- | |||
|- | |- | ||
|28581 | |28581 | ||
|1SN0 | |1SN0 | ||
|Eneqvist T, Lundberg E, Karlsson A, Huang S, Santos CR, Power DM, Sauer-Eriksson AEHigh resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxineJ. Biol. Chem. v279, p.26411-26416 | |Eneqvist T, Lundberg E, Karlsson A, Huang S, Santos CR, Power DM, Sauer-Eriksson AEHigh resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxineJ. Biol. Chem. v279, p.26411-26416 | ||
- | |||
|- | |- | ||
|3173 | |3173 | ||
|1Y0X | |1Y0X | ||
|Sandler B, Webb P, Apriletti JW, Huber BR, Togashi M, Cunha Lima ST, Juric S, Nilsson S, Wagner R, Fletterick RJ, Baxter JDThyroxine-thyroid hormone receptor interactionsJ. Biol. Chem. v279, p.55801-55808 | |Sandler B, Webb P, Apriletti JW, Huber BR, Togashi M, Cunha Lima ST, Juric S, Nilsson S, Wagner R, Fletterick RJ, Baxter JDThyroxine-thyroid hormone receptor interactionsJ. Biol. Chem. v279, p.55801-55808 | ||
- | |||
|- | |- | ||
|5764 | |5764 | ||
Line 84: | Line 80: | ||
|2ROX | |2ROX | ||
|Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 | |Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 | ||
- | |||
|- | |- | ||
|67282 | |67282 | ||
Line 94: | Line 89: | ||
|1ETA | |1ETA | ||
|Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 | |Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 | ||
- | |||
|- | |- | ||
|899 | |899 | ||
|1ETB | |1ETB | ||
|Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 | |Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 | ||
- | |||
|- | |- | ||
|} | |} |
Revision as of 09:11, 24 October 2008
Pubchem(5819)
The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
Lipinski’s “Rule of Five” Prediction for a Compound’s ABSORPTION OR PERMEABILITY PROPERTIES.
4 | 3 | 2 | 1 | 0 |
---|---|---|---|---|
GOOD | INDETERMINATE | INDETERMINATE | INDETERMINATE | POOR |
KEGG Pathway(C01829)
- Tyrosine metabolism
- Neuroactive ligand-receptor interaction
- Autoimmune thyroid disease
Comment Thyroid hormone synthesized on thyroglobulin
MMDB ID | PDB ID | Reference |
---|---|---|
18746 | 1ICT | Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 |
19209 | 1IE4 | Wojtczak ACrystal structure of rat transthyretin at 2.5 A resolution: first report on a unique tetrameric structureActa Biochim. Pol. v44, p.505-517 |
22897 | 1HK1 | Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
22898 | 1HK2 | Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
22893 | 1HK3 | Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
22900 | 1HK4 | Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
22901 | 1HK5 | Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry SStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaProc. Natl. Acad. Sci. U. S. A. v100, p.6440-6445 |
28581 | 1SN0 | Eneqvist T, Lundberg E, Karlsson A, Huang S, Santos CR, Power DM, Sauer-Eriksson AEHigh resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxineJ. Biol. Chem. v279, p.26411-26416 |
3173 | 1Y0X | Sandler B, Webb P, Apriletti JW, Huber BR, Togashi M, Cunha Lima ST, Juric S, Nilsson S, Wagner R, Fletterick RJ, Baxter JDThyroxine-thyroid hormone receptor interactionsJ. Biol. Chem. v279, p.55801-55808 |
5764 | 2CEO | Zhou A, Wei Z, Read RJ, Carrell RWStructural mechanism for the carriage and release of thyroxine in the bloodProc. Natl. Acad. Sci. U. S. A. v103, p.13321-13326
The hormones that most directly control tissue activities in health and disease are delivered by two noninhibitory members of the serpin family of protease inhibitors, thyroxine-binding globulin (TBG) and corticosteroid-binding globulin. The structure of TBG bound to tetra-iodo thyroxine, solved here at 2.8 A, shows how the thyroxine is carried in a surface pocket on the molecule.... |
5764 | 2ROX | Wojtczak A, Luft JR, Cody VStructural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complexJ. Biol. Chem. v268, p.6202-6206 |
67282 | 2RIW | Description The Reactive Loop Cleaved Human Thyroxine Binding Globulin Complexed With Thyroxine.
Deposition: Zhou A, Wei Z, Stanley PLD, Read RJ, Stein PE, Carrell RW, 2007/10/12 |
898 | 1ETA | Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 |
899 | 1ETB | Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen LThe x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolutionJ. Biol. Chem. v268, p.2416-2424 |
Physical Property | Value | Units | Temp (deg C) | Source |
---|---|---|---|---|
Melting Point | 235.5 | deg C | EXP | |
log P (octanol-water) | 4.120 | (none) | EST | |
Water Solubility | 1.05E-04 | mg/L | 25 | EST |
Vapor Pressure | 1.24E-17 | mm Hg | 25 | EST |
Henry's Law Constant | 7.91E-19 | atm-m3/mole | 25 | EST |
Atmospheric OH Rate Constant | 4.17E-11 | cm3/molecule-sec | 25 | EST |
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 328ug/kg (0.328mg/kg) | CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP,VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Pediatrics. Vol. 73, Pg. 313, 1984.Link to PubMed |
man | TDLo | oral | 63ug/kg (0.063mg/kg) | PTIONS",CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Journal of Toxicology, Clinical Toxicology. Vol. 20, Pg. 517, 1983.,Link to PubMed |
man | TDLo | oral | 10286ug/kg (10.286mg/kg) | BEHAVIORAL: EXCITEMENT,CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP,
GASTROINTESTINAL: NAUSEA OR VOMITING | Veterinary and Human Toxicology. Vol. 41, Pg. 323, 1999.Link to PubMed |
women | TDLo | oral | 400ug/kg/2D-I (0.4mg/kg) | BEHAVIORAL: COMA,CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Intensive Care Medicine. Vol. 13, Pg. 33, 1987.Link to PubMed |